Jade Biosciences, Inc. (JBIO) Stock Forecast & Price Target
Jade Biosciences, Inc. · NASDAQ
$19.95-0.13 (-0.65%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Jade Biosciences, Inc, 6 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $25.00 to $74.00 (about 3.0x), a sign of real disagreement on valuation. The average target of $46.00 sits 131% above the current $19.95. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 5 to 6 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.57 next quarter toward $-2.28 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Moderate Buy
Strong Buy00%
Buy6100%
Hold00%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Jade Biosciences, Inc.
As of Jul, 6 of 6 firms rate JBIO a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
JBIO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.57
Range $-0.57 – $-0.57 · 1 analysts
Next period, 1 analysts expect Jade Biosciences, Inc. to earn $-0.57 a share (range $-0.57 – $-0.57), versus — a year earlier. Full-year consensus is $-2.28, growing to $-2.28 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Jade Biosciences, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on JBIO.
#1
Laura Chico
Wedbush · Rank #122
Buy
$45.00+125.6% to target
Overall win rate
40%
+ Follow
#2
Arthur He
HC Wainwright & Co. · Rank #150
Buy
$55.00+175.7% to target
Overall win rate
48%
+ Follow
#3
Julian Harrison
BTIG
Buy
$74.00+270.9% to target
Coverage
—
+ Follow
#4
Vamil Divan
Guggenheim
Buy
$47.00+135.6% to target
Coverage
—
+ Follow
#5
Akash Tewari
Jefferies
Buy
$40.00+100.5% to target
Coverage
—
+ Follow
JBIO stock forecast FAQ
What is JBIO's average 12-month price target?+
The 6 analysts with a live target average $46.00 for Jade Biosciences, Inc. over the next 12 months, ranging from a $74.00 high to a $25.00 low.
Is JBIO stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 6 analyst ratings, 6 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for JBIO?+
The Street-high target is $74.00 (BTIG), and the Street-low is $25.00 (Clear Street). The average of all 6 active targets is $46.00.
How many Wall Street analysts cover JBIO?+
6 analysts have an active rating on Jade Biosciences, Inc., and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering JBIO?+
Among analysts who currently cover JBIO, Laura Chico of Wedbush has the strongest overall Quantellect track record (Rank #122). Their current call is Buy with a $45.00 target.
What is Jade Biosciences, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.57 per share (range $-0.57 – $-0.57) across 1 analysts. Full-year EPS is projected at $-2.28, rising to $-2.28 the following year.
How much revenue is Jade Biosciences, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading JBIO lately?+
As of Jul, 6 of 6 firms rate JBIO a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their JBIO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
